Abstract

The present invention provides a method for preparing liposomes encapsulating an anticancer agent, the method comprising irradiation with blue light or near-infrared light. In addition, the present invention provides a pharmaceutical composition for treating cancer, comprising liposomes that encapsulate an anticancer agent and are obtained by the preparation method.

IPC Classes  ?

• A61K 9/127 - Synthetic bilayered vehicles, e.g. liposomes or liposomes with cholesterol as the only non-phosphatidyl surfactant
• A61K 31/704 - Compounds having saccharide radicals attached to non-saccharide compounds by glycosidic linkages attached to a carbocyclic compound, e.g. phloridzin attached to a condensed carbocyclic ring system, e.g. sennosides, thiocolchicosides, escin, daunorubicin, digitoxin
• A61K 31/337 - Heterocyclic compounds having oxygen as the only ring hetero atom, e.g. fungichromin having four-membered rings, e.g. taxol
• A61P 35/00 - Antineoplastic agents

Abstract

The present invention provides a pharmaceutical composition for treating osteoarthritis, comprising mitochondria-encapsulated cell membrane fusogenic liposomes as an active ingredient.

IPC Classes  ?

• A61K 9/127 - Synthetic bilayered vehicles, e.g. liposomes or liposomes with cholesterol as the only non-phosphatidyl surfactant
• A61K 35/28 - Bone marrowHaematopoietic stem cellsMesenchymal stem cells of any origin, e.g. adipose-derived stem cells
• A61P 19/02 - Drugs for skeletal disorders for joint disorders, e.g. arthritis, arthrosis

Abstract

The present invention provides: nanocomposites for temporary photoperforation of a cell membrane, formed by combining (i) gold nanoparticle and (ii) upconverting nanoparticles comprising ytterbium (Yb3+) and erbium (Er3+); and a pharmaceutical composition comprising same. The nanocomposite according to the present invention enables the use of near-infrared region light, which can effectively penetrate tissue, and enables temporary photoperforation through the formation of vapor nanobubbles caused by a momentary increase in temperature, and thus can promote the penetration of molecules (for example, drugs) into the plasma membrane/cell membrane.

IPC Classes  ?

• A61K 9/00 - Medicinal preparations characterised by special physical form
• A61K 9/51 - Nanocapsules
• A61K 31/519 - PyrimidinesHydrogenated pyrimidines, e.g. trimethoprim ortho- or peri-condensed with heterocyclic rings
• A61P 19/02 - Drugs for skeletal disorders for joint disorders, e.g. arthritis, arthrosis

Abstract

The present invention relates to a mental disease prediction and diagnosis classification apparatus by means of a natural language expression and a method therefor. According to the present invention, the mental disease prediction and diagnosis classification apparatus comprises: an input unit that receives, as an input from a medical personnel terminal, mental disease natural language expression information of a patient to be diagnosed; a preprocessing unit that tokenizes the mental disease natural language expression information by using a natural language processing (NLP) algorithm; and a disease prediction unit that inputs the tokenized mental disease natural language expression information into a pre-built diagnosis classification model to classify the corresponding patient to be diagnosed as having any one mental disease from among a generalized anxiety disorder, a panic disorder, a post-traumatic stress disorder, obsessive-compulsive thought or rumination, a remarkable obsessive-compulsive behavior, a social phobia, a specific phobia, agoraphobia, an adjustment disorder, an acute stress response, and a mixed obsessive-compulsive thought and behavior.

IPC Classes  ?

• G16H 50/20 - ICT specially adapted for medical diagnosis, medical simulation or medical data miningICT specially adapted for detecting, monitoring or modelling epidemics or pandemics for computer-aided diagnosis, e.g. based on medical expert systems
• G16H 50/50 - ICT specially adapted for medical diagnosis, medical simulation or medical data miningICT specially adapted for detecting, monitoring or modelling epidemics or pandemics for simulation or modelling of medical disorders
• G16H 10/60 - ICT specially adapted for the handling or processing of patient-related medical or healthcare data for patient-specific data, e.g. for electronic patient records
• G16H 10/20 - ICT specially adapted for the handling or processing of patient-related medical or healthcare data for electronic clinical trials or questionnaires
• G16H 50/70 - ICT specially adapted for medical diagnosis, medical simulation or medical data miningICT specially adapted for detecting, monitoring or modelling epidemics or pandemics for mining of medical data, e.g. analysing previous cases of other patients
• A61B 5/16 - Devices for psychotechnicsTesting reaction times
• G06F 40/284 - Lexical analysis, e.g. tokenisation or collocates
• G06F 18/241 - Classification techniques relating to the classification model, e.g. parametric or non-parametric approaches

Abstract

Provided is a method for preventing or treating optic neuropathy, comprising administering a pharmaceutical composition including neural progenitor cells as an active ingredient, where the neural progenitor cells not only exhibit remarkably superior neuroprotective and pro-regenerative effects compared to mesenchymal stem cells such as placenta-derived stem cells (e.g., PSCs), but also can be administered by non-invasive and safe subtenon injection, and therefore the method may be advantageously used as a cell therapy for treating optic neuropathy.

IPC Classes  ?

• A61K 35/30 - NervesBrainEyesCorneal cellsCerebrospinal fluidNeuronal stem cellsNeuronal precursor cellsGlial cellsOligodendrocytesSchwann cellsAstrogliaAstrocytesChoroid plexusSpinal cord tissue
• A61P 27/02 - Ophthalmic agents

Abstract

The present invention relates to a method for isolating mitochondria. The method of the present invention has an advantage in that mitochondria can be effectively obtained without a high-speed centrifugation device. In addition, since the high-speed centrifugation device is not used, a mitochondria isolation time can be shortened, and nucleic acids or DAMP substances capable of causing inflammation can be effectively removed.

IPC Classes  ?

• B01D 61/14 - UltrafiltrationMicrofiltration
• C12N 5/071 - Vertebrate cells or tissues, e.g. human cells or tissues
• C12M 1/00 - Apparatus for enzymology or microbiology

Abstract

The present invention relates to a composition for storing isolated mitochondria and a use thereof. The storage composition of the present invention can maintain the activity of mitochondria isolated from cells, tissues, plasma, and the like for a long period of time, and thus can be used in various ways.

IPC Classes  ?

• A01N 1/02 - Preservation of living parts
• C12N 5/071 - Vertebrate cells or tissues, e.g. human cells or tissues
• A61K 35/51 - Umbilical cordUmbilical cord bloodUmbilical stem cells
• A61K 35/16 - Blood plasmaBlood serum
• A61K 9/00 - Medicinal preparations characterised by special physical form
• C12N 5/078 - Cells from blood or from the immune system

Abstract

The present invention relates to an apparatus and kit for isolating mitochondria. The device and kit of the present invention have an advantage in that mitochondria can be effectively obtained without a high-speed centrifugation device. In addition, a mitochondrial isolation time can be shortened due to nonuse of the high-speed centrifugation device, and nucleic acids or DAMP substances capable of causing inflammation can be effectively removed.

IPC Classes  ?

• B01D 61/14 - UltrafiltrationMicrofiltration
• C12N 5/071 - Vertebrate cells or tissues, e.g. human cells or tissues
• C12M 1/00 - Apparatus for enzymology or microbiology

Abstract

A method of preventing or treating poor ovarian response syndrome, including administering a pharmaceutical composition containing an RGMc-derived protein. A pharmaceutical composition for preventing, treating or ameliorating infertility, containing an RGMc-derived protein, where the infertility is infertility due to poor ovarian response syndrome. A pharmaceutical composition for promoting pregnancy, containing an RGMc-derived protein.

IPC Classes  ?

• A61K 38/17 - Peptides having more than 20 amino acidsGastrinsSomatostatinsMelanotropinsDerivatives thereof from animalsPeptides having more than 20 amino acidsGastrinsSomatostatinsMelanotropinsDerivatives thereof from humans
• A61P 15/08 - Drugs for genital or sexual disordersContraceptives for gonadal disorders or for enhancing fertility, e.g. inducers of ovulation or of spermatogenesis

Abstract

A method for preparing pluripotent stem cell-derived hematopoietic stem cells and a method of constructing a humanized mouse model with the prepared hematopoietic stem cells. The method of preparing the hematopoietic stem cells identified an optimal differentiation condition according to a combination of low-molecular-weight compounds and protein growth factors without gene insertion, and thus may differentiate hematopoietic stem cells from pluripotent stem cells at high yield.

IPC Classes  ?

• C12N 5/0789 - Stem cellsMultipotent progenitor cells
• A01K 67/0271 - Chimeric vertebrates, e.g. comprising exogenous cells

Abstract

The present invention pertains to an anticancer composition containing IF1 (ATPase inhibitory factor 1). The IF1 (ATPase inhibitory factor 1) according to the present invention has the effect of releasing extracellular ATP, induces cytotoxicity in various cancer cells and exhibits anticancer efficacy, and is thus very useful as an active ingredient of a powerful anticancer agent.

IPC Classes  ?

• A61K 38/17 - Peptides having more than 20 amino acidsGastrinsSomatostatinsMelanotropinsDerivatives thereof from animalsPeptides having more than 20 amino acidsGastrinsSomatostatinsMelanotropinsDerivatives thereof from humans
• A23L 33/17 - Amino acids, peptides or proteins
• A61P 35/00 - Antineoplastic agents

Abstract

The present invention relates to a method for valuation of unstructured medical data. More specifically, the present invention relates to a valuation method that takes into account the characteristics of medical data in addition to the existing valuation methods of market approach, cost approach, and income approach. According to the valuation method and a server of the present invention, a reasonable value can be set for medical data, thereby preventing unstandardized price setting in a medical data exchange and providing a reasonable standard. In addition, by establishing reasonable price setting standards, the method can be widely utilized in the rapidly growing medical data-related market.

IPC Classes  ?

• G16H 10/00 - ICT specially adapted for the handling or processing of patient-related medical or healthcare data
• G16H 40/20 - ICT specially adapted for the management or administration of healthcare resources or facilitiesICT specially adapted for the management or operation of medical equipment or devices for the management or administration of healthcare resources or facilities, e.g. managing hospital staff or surgery rooms
• G16H 30/20 - ICT specially adapted for the handling or processing of medical images for handling medical images, e.g. DICOM, HL7 or PACS
• G06Q 10/06 - Resources, workflows, human or project managementEnterprise or organisation planningEnterprise or organisation modelling

Abstract

The present invention relates to a drug delivery composition comprising cationic gelatin and alginate. A drug delivery composition comprising cationic gelatin and alginate, according to one embodiment, uses gelatin that is biocompatible and biodegradable and thus safe enough to be used in food, and therefore has excellent safety due to being free of cytotoxicity, and can deliver an active ingredient (a compound, polynucleotide, or polypeptide) to an individual in need thereof at a remarkable level, and thus has high utility as a delivery carrier for the active ingredient (a compound, polynucleotide, or polypeptide).

IPC Classes  ?

• A61K 9/10 - DispersionsEmulsions
• A61K 47/42 - ProteinsPolypeptidesDegradation products thereofDerivatives thereof, e.g. albumin, gelatin or zein
• A61K 47/36 - PolysaccharidesDerivatives thereof, e.g. gums, starch, alginate, dextrin, hyaluronic acid, chitosan, inulin, agar or pectin
• A61K 31/7105 - Natural ribonucleic acids, i.e. containing only riboses attached to adenine, guanine, cytosine or uracil and having 3'-5' phosphodiester links
• A61K 38/18 - Growth factorsGrowth regulators
• A61K 31/713 - Double-stranded nucleic acids or oligonucleotides
• A61K 48/00 - Medicinal preparations containing genetic material which is inserted into cells of the living body to treat genetic diseasesGene therapy
• A61P 17/02 - Drugs for dermatological disorders for treating wounds, ulcers, burns, scars, keloids, or the like

Abstract

A composition, kit, and method for measuring the expression levels of STX 12 and Delphilin proteins, fragments thereof, or polynucleotides encoding these proteins according to an aspect can efficiently diagnose optic nerve injury-related diseases, whereby the treatment effects of optic nerve injury therapeutics can be maximized, and candidate substances for treating optic nerve injuries can be efficiently screened.

IPC Classes  ?

• C12Q 1/6883 - Nucleic acid products used in the analysis of nucleic acids, e.g. primers or probes for diseases caused by alterations of genetic material
• G01N 33/68 - Chemical analysis of biological material, e.g. blood, urineTesting involving biospecific ligand binding methodsImmunological testing involving proteins, peptides or amino acids

Abstract

Provided are a biodegradable polymer scaffold including bioactive materials and methods of manufacturing the same. The biodegradable polymer scaffold, preventing inflammatory responses caused by acidic substances produced during a degradation process, has easily controllable mechanical strength, and includes bioactive materials derived from cells of target tissues, and thus may induce tissue regeneration more effectively.

IPC Classes  ?

• A61L 27/44 - Composite materials, i.e. layered or containing one material dispersed in a matrix of the same or different material having a macromolecular matrix
• A61L 27/10 - Ceramics or glasses
• A61L 27/36 - Materials for prostheses or for coating prostheses containing ingredients of undetermined constitution or reaction products thereof
• A61L 27/54 - Biologically active materials, e.g. therapeutic substances
• A61L 27/56 - Porous or cellular materials
• A61L 27/58 - Materials at least partially resorbable by the body
• A61L 31/00 - Materials for other surgical articles
• A61L 31/02 - Inorganic materials
• A61L 31/12 - Composite materials, i.e. layered or containing one material dispersed in a matrix of the same or different material
• A61L 31/14 - Materials characterised by their function or physical properties
• A61L 31/16 - Biologically active materials, e.g. therapeutic substances

Abstract

The present invention relates to apoptosis-induced stem cells, a production method therefor, and a pharmaceutical composition containing same for preventing or treating inflammatory or renal diseases. The cells and compositions containing same as an active ingredient according to one aspect are characterized by an increased expression of IL-10 without including a cryoprotectant and can be effectively useful for the prevention or treatment of inflammatory or renal diseases.

IPC Classes  ?

• C12N 5/071 - Vertebrate cells or tissues, e.g. human cells or tissues
• C12N 5/0735 - Embryonic stem cellsEmbryonic germ cells
• C12N 5/074 - Adult stem cells
• C07K 14/54 - Interleukins [IL]
• A61K 35/545 - Embryonic stem cellsPluripotent stem cellsInduced pluripotent stem cellsUncharacterised stem cells
• A61P 29/00 - Non-central analgesic, antipyretic or antiinflammatory agents, e.g. antirheumatic agentsNon-steroidal antiinflammatory drugs [NSAID]
• A61P 13/12 - Drugs for disorders of the urinary system of the kidneys

Abstract

A pharmaceutical composition for preventing or treating a stroke, the pharmaceutical composition comprising, as an active ingredient, neural precursor cells differentiated from HLA homozygous human induced pluripotent stem cells (hiPSC-NPC), wherein, through the use of a homozygous type, immunorejection may be eliminated and stable therapeutic effects for stroke may be exhibited.

IPC Classes  ?

• A61K 35/30 - NervesBrainEyesCorneal cellsCerebrospinal fluidNeuronal stem cellsNeuronal precursor cellsGlial cellsOligodendrocytesSchwann cellsAstrogliaAstrocytesChoroid plexusSpinal cord tissue
• A61P 9/10 - Drugs for disorders of the cardiovascular system for treating ischaemic or atherosclerotic diseases, e.g. antianginal drugs, coronary vasodilators, drugs for myocardial infarction, retinopathy, cerebrovascula insufficiency, renal arteriosclerosis
• C12N 5/0797 - Stem cellsProgenitor cells

Abstract

Provided are: an anxiety disorder diagnostic composition and diagnostic kit, including an agent for measuring the expression level of mRNA of an acyl-CoA cholesterol acyltransferase-2 (ACAT2) gene for diagnosis of anxiety disorders or a protein encoded by the gene; and a diagnostic method comprising a step of measuring the expression level of mRNA of an ACAT2 gene or a protein encoded by the gene.

IPC Classes  ?

• C12Q 1/6883 - Nucleic acid products used in the analysis of nucleic acids, e.g. primers or probes for diseases caused by alterations of genetic material
• G01N 33/68 - Chemical analysis of biological material, e.g. blood, urineTesting involving biospecific ligand binding methodsImmunological testing involving proteins, peptides or amino acids

Abstract

This novel compound can remarkably alleviate thickened and dried skin conditions, which are symptoms of inflammatory skin diseases, especially atopic dermatitis, and can remarkably inhibit the expression of representative markers expressed in atopic dermatitis, and thus can be widely used in fields for treating atopic dermatitis.

IPC Classes  ?

• A61K 31/352 - Heterocyclic compounds having oxygen as the only ring hetero atom, e.g. fungichromin having six-membered rings with one oxygen as the only ring hetero atom condensed with carbocyclic rings, e.g. cannabinols, methantheline
• A61P 17/00 - Drugs for dermatological disorders
• A61P 29/00 - Non-central analgesic, antipyretic or antiinflammatory agents, e.g. antirheumatic agentsNon-steroidal antiinflammatory drugs [NSAID]
• A23L 33/10 - Modifying nutritive qualities of foodsDietetic productsPreparation or treatment thereof using additives
• A61K 8/49 - Cosmetics or similar toiletry preparations characterised by the composition containing organic compounds containing heterocyclic compounds
• A61Q 19/00 - Preparations for care of the skin
• A61K 9/00 - Medicinal preparations characterised by special physical form

Abstract

The present invention relates to a biomarker for predicting immunotherapeutic responsiveness based on spatial transcriptome analysis and uses thereof and, in particular, to: a marker composition for predicting the responsiveness of cancer patients to immunotherapy; a composition for predicting the responsiveness of cancer patients to immunotherapy; a kit for predicting the responsiveness of cancer patients to immunotherapy, comprising the composition; a method for providing information for predicting the responsiveness of cancer patients to immunotherapy; and a method for providing information for predicting the survival prognosis of cancer patients. The biomarker for predicting immunotherapeutic responsiveness, according to the present invention, was discovered by applying spatial transcriptome technology and analyzing cell group-specific gene expression values according to location information of cells in tissue sections, and can more precisely and accurately predict the responsiveness of cancer patients to immunotherapy and the survival prognosis of patients, thus enabling suitable treatments for patient groups, which may result in improved therapeutic effects and a reduction in pain and costs for patients.

IPC Classes  ?

• C12Q 1/6886 - Nucleic acid products used in the analysis of nucleic acids, e.g. primers or probes for diseases caused by alterations of genetic material for cancer
• G01N 33/574 - ImmunoassayBiospecific binding assayMaterials therefor for cancer

Abstract

The present invention provides a pharmaceutical composition containing N-nonyldeoxynojirimycin for the suppression, alleviation, or treatment of skin itching; and a cosmetic composition for the suppression, alleviation, or palliation of skin itching.

IPC Classes  ?

• A61K 31/445 - Non-condensed piperidines, e.g. piperocaine
• A61P 17/00 - Drugs for dermatological disorders
• A61P 17/04 - Antipruritics
• A61K 8/49 - Cosmetics or similar toiletry preparations characterised by the composition containing organic compounds containing heterocyclic compounds
• A61Q 19/00 - Preparations for care of the skin

Abstract

The present invention relates to a medium composition for inducing differentiation from a stem cell to a macrophage. According to a medium composition for inducing differentiation from a stem cell to a macrophage, according to one aspect, there are effects of improving the efficiency of differentiation into a macrophage, and improving the expression of a macrophage-specific marker.

IPC Classes  ?

• C12N 5/078 - Cells from blood or from the immune system

Abstract

The present invention relates to a medium composition for inducing differentiation from stem cells to macrophages. The medium composition for inducing differentiation from stem cells to macrophages according to one aspect, can provide the effects of increasing the efficiency of differentiation from stem cells to macrophages and enhancing the expression of macrophage-specific markers.

IPC Classes  ?

• C12N 5/0786 - MonocytesMacrophages

Abstract

The present invention relates to a composition for endometrial regeneration containing a uterus derived decellularized extracellular matrix (UdECM) and a manufacturing method therefor. Characterized by containing uterus derived decellularized extracellular matrix (UdECM), the composition can exhibit the effect of enhancing the regeneration, receptivity, and implantation capabilities of the endometrium.

IPC Classes  ?

• A61K 35/48 - Reproductive organs
• A61K 38/39 - Connective tissue peptides, e.g. collagen, elastin, laminin, fibronectin, vitronectin, cold insoluble globulin [CIG]
• A61K 38/17 - Peptides having more than 20 amino acidsGastrinsSomatostatinsMelanotropinsDerivatives thereof from animalsPeptides having more than 20 amino acidsGastrinsSomatostatinsMelanotropinsDerivatives thereof from humans
• A61P 15/02 - Drugs for genital or sexual disordersContraceptives for disorders of the vagina
• C09D 11/00 - Inks
• A61L 27/36 - Materials for prostheses or for coating prostheses containing ingredients of undetermined constitution or reaction products thereof
• C12N 5/071 - Vertebrate cells or tissues, e.g. human cells or tissues
• B01L 3/00 - Containers or dishes for laboratory use, e.g. laboratory glasswareDroppers

Abstract

The present invention provides an analytic method comprising a step for measuring the expression level of a gene encoding at least one deubiquitinating enzyme, selected from the group consisting of USP3, USP9X, USP26, USP34, COPS5, OTUD6A, and OTUD7A, in a tumor cell sample isolated in vitro from a patient with ovarian cancer resistant to paclitaxel, which is an anticancer drug widely used in the treatment of ovarian cancer, the expression level of the gene being measured in order to provide information needed to diagnose the patient with ovarian cancer. Also, the present invention provides a kit for diagnosing ovarian cancer resistant to paclitaxel, the kit comprising a molecule capable of measuring the expression level of a gene encoding the protein.

IPC Classes  ?

• C12Q 1/6886 - Nucleic acid products used in the analysis of nucleic acids, e.g. primers or probes for diseases caused by alterations of genetic material for cancer
• C12Q 1/6851 - Quantitative amplification

Abstract

The present invention relates to a biomarker for diagnosing infertility in elderly women and a use thereof, and can not only non-invasively diagnose infertility in elderly women, but can also be a useful new target for infertility treatment.

IPC Classes  ?

• C12Q 1/6883 - Nucleic acid products used in the analysis of nucleic acids, e.g. primers or probes for diseases caused by alterations of genetic material
• G01N 33/68 - Chemical analysis of biological material, e.g. blood, urineTesting involving biospecific ligand binding methodsImmunological testing involving proteins, peptides or amino acids

Abstract

The present invention relates to a novel compound, and a composition for preventing or treating HER2-positive cancer, comprising same. The novel compound of the present invention can suppress the level of HER2 by inhibiting the protein-protein interaction between ELF3 and MED23, and thereby has a significant anticancer effect. Moreover, even in cases of resistance to trastuzumab, which is conventionally used clinically as a cancer treatment, treatment with the novel compound of the present invention showed a remarkable level of anticancer efficacy. Therefore, it is expected that the novel compound of the present invention can be widely used in the field of cancer treatment.

IPC Classes  ?

• C07D 307/40 - Radicals substituted by oxygen atoms
• A61K 31/341 - Heterocyclic compounds having oxygen as the only ring hetero atom, e.g. fungichromin having five-membered rings with one oxygen as the only ring hetero atom, e.g. isosorbide not condensed with another ring, e.g. ranitidine, furosemide, bufetolol, muscarine
• A61K 31/12 - Ketones
• A61K 31/381 - Heterocyclic compounds having sulfur as a ring hetero atom having five-membered rings
• A61K 31/4155 - 1,2-Diazoles not condensed and containing further heterocyclic rings
• A61K 31/415 - 1,2-Diazoles
• A61P 35/00 - Antineoplastic agents
• C07D 333/06 - Heterocyclic compounds containing five-membered rings having one sulfur atom as the only ring hetero atom not condensed with other rings not substituted on the ring sulfur atom with only hydrogen atoms, hydrocarbon or substituted hydrocarbon radicals, directly attached to the ring carbon atoms
• C07D 405/04 - Heterocyclic compounds containing both one or more hetero rings having oxygen atoms as the only ring hetero atoms, and one or more rings having nitrogen as the only ring hetero atom containing two hetero rings directly linked by a ring-member-to-ring- member bond
• C07D 231/06 - Heterocyclic compounds containing 1,2-diazole or hydrogenated 1,2-diazole rings not condensed with other rings having one double bond between ring members or between a ring member and a non-ring member

Abstract

The present invention provides: a Bax protein variant in which lysine at position 128, lysine at position 190, or lysines at positions 128 and 190 in a Bax protein is(are) substituted with arginine; a method for increasing the half-life of a Bax protein, the method comprising substituting lysine at position 128, lysine at position 190, or lysines at positions 128 and 190 in the Bax protein with arginine; a pharmaceutical composition comprising the Bax protein variant; and a method for screening for an anticancer substance. The Bax protein variant according to the present invention can inhibit a mechanism of protein degradation through ubiquitination and exhibits a longer half-life than wild-type Bax.

IPC Classes  ?

• C07K 14/47 - Peptides having more than 20 amino acidsGastrinsSomatostatinsMelanotropinsDerivatives thereof from animalsPeptides having more than 20 amino acidsGastrinsSomatostatinsMelanotropinsDerivatives thereof from humans from vertebrates from mammals
• A61P 35/00 - Antineoplastic agents
• G01N 33/50 - Chemical analysis of biological material, e.g. blood, urineTesting involving biospecific ligand binding methodsImmunological testing
• A61K 38/00 - Medicinal preparations containing peptides

Abstract

The present invention provides an analytic method to provide information needed for the diagnosis of patients with ovarian cancer resistant to cisplatin, which is an anticancer drug widely used in the treatment of ovarian cancer, the method comprising a step of measuring the expression level of a gene encoding at least one proteolytic enzyme selected from the group consisting of USP12, USP17, USP51, OTUD1, and PSMD14, in tumor cell samples isolated in vitro from ovarian cancer patients. Also, the present invention provides a kit for diagnosing ovarian cancer resistant to cisplatin, the kit comprising a molecule capable of measuring the expression level of a gene encoding the protein.

IPC Classes  ?

• C12Q 1/6886 - Nucleic acid products used in the analysis of nucleic acids, e.g. primers or probes for diseases caused by alterations of genetic material for cancer
• C12Q 1/6851 - Quantitative amplification
• C12Q 1/6837 - Enzymatic or biochemical coupling of nucleic acids to a solid phase using probe arrays or probe chips
• C12Q 1/37 - Measuring or testing processes involving enzymes, nucleic acids or microorganismsCompositions thereforProcesses of preparing such compositions involving hydrolase involving peptidase or proteinase
• C12N 9/48 - Hydrolases (3.) acting on peptide bonds, e.g. thromboplastin, leucine aminopeptidase (3.4)

Abstract

The present invention relates to a protein for preventing or treating brain-nervous system diseases and a pharmaceutical composition comprising same. A protein or polynucleotide according to one aspect has excellent therapeutic effects in stroke animal models, cerebral palsy animal models, dementia models, Parkinson's disease models, and autism models, and thus can be useful in the prevention or treatment of diseases in the brain-nervous system which is difficult to regenerate.

IPC Classes  ?

• C07K 14/47 - Peptides having more than 20 amino acidsGastrinsSomatostatinsMelanotropinsDerivatives thereof from animalsPeptides having more than 20 amino acidsGastrinsSomatostatinsMelanotropinsDerivatives thereof from humans from vertebrates from mammals
• A61P 25/00 - Drugs for disorders of the nervous system
• C12N 15/62 - DNA sequences coding for fusion proteins
• A61K 38/00 - Medicinal preparations containing peptides

Abstract

2α2α2α2α2α2α2α analogue, according to the present invention, can exhibit the effect of treating or preventing kidney damage caused by antibiotics. Particularly, since the effect can be achieved without influencing the antibacterial effectiveness of antibiotics, the composition can be effectively used as a material for treating, alleviating or preventing kidney diseases.

IPC Classes  ?

• A61K 31/5575 - Eicosanoids, e.g. leukotrienes having a cyclopentane ring, e.g. prostaglandin E2, prostaglandin F2-alpha
• A61P 13/12 - Drugs for disorders of the urinary system of the kidneys
• A23L 33/10 - Modifying nutritive qualities of foodsDietetic productsPreparation or treatment thereof using additives

Abstract

One aspect provides a physiologically based pharmacokinetic core model which may be commonly applied to two or more compounds that share the same core structure, and a method of constructing the physiologically based pharmacokinetic core model. According to the physiologically based pharmacokinetic core model and the method of constructing the physiologically based pharmacokinetic core model, there is the effect of conducting exposure evaluation simply only by deriving a distribution coefficient, without constructing a separate PBPK model for each individual compound.

IPC Classes  ?

• G16C 20/30 - Prediction of properties of chemical compounds, compositions or mixtures

Abstract

The present invention relates to a medium composition for producing nasal mucosal organoids and a method for producing nasal mucosal organoids, the method comprising the step of culturing cells derived from a nasal mucosal tissue in the medium composition. The nasal mucosal organoids produced according to the present invention exhibit high tissue similarity to human nasal mucosal tissues and can be directly infected by viruses such as the coronavirus, or bacteria. Consequently, the method for producing nasal mucosal organoids according to the present invention can be utilized for producing nasal mucosal organoids that closely resemble the morphology and function of biological tissues. Furthermore, the produced nasal mucosal organoids can be beneficially employed for the screening or efficacy evaluation of treatments/vaccines against viral or bacterial infections.

IPC Classes  ?

• C12N 5/071 - Vertebrate cells or tissues, e.g. human cells or tissues
• G01N 33/50 - Chemical analysis of biological material, e.g. blood, urineTesting involving biospecific ligand binding methodsImmunological testing
• A61P 31/14 - Antivirals for RNA viruses

Abstract

The present invention relates to a method for preparing pancreatic cancer organoids mimicking a cancer microenvironment. In addition, the present invention relates to a method for evaluating the efficacy of pancreatic cancer organoids prepared by the above preparation method and an anticancer agent using the pancreatic cancer organoids, and a screening method. The preparation method according to the present invention can prepare pancreatic cancer organoids that perfectly mimic a cancer microenvironment. Accordingly, the pancreatic cancer organoids prepared by the above method can directly observe the effects on cancer cell proliferation/metastasis and anticancer agent resistance, and can be used to develop a drug screening platform to confirm patient-specific anticancer agent resistance in advance. In addition, observation of gene expression regulation according to drug treatment can contribute to the study of molecular mechanisms for the purpose of cancer treatment.

IPC Classes  ?

• C12N 5/09 - Tumour cells
• C12N 5/071 - Vertebrate cells or tissues, e.g. human cells or tissues
• G01N 33/50 - Chemical analysis of biological material, e.g. blood, urineTesting involving biospecific ligand binding methodsImmunological testing

Abstract

According to a composition including a cationic substance as an active ingredient according to one aspect, the stability of perforin protein is increased to induce the accumulation of intracellular perforin proteins, thereby increasing the activity of immune cells.

IPC Classes  ?

• A61K 31/785 - Polymers containing nitrogen
• C12N 5/0783 - T cellsNK cellsProgenitors of T or NK cells
• A61P 35/00 - Antineoplastic agents

Abstract

An operation method for a vaccine side effect prediction and analysis apparatus, according to an embodiment of the present invention, comprises the steps of: acquiring subject variable information about vaccine side effect prediction and analysis subjects; acquiring side effect variable information corresponding to the subject variable information; acquiring an estimated vaccine side effect classification model and probability information by inputting the subject variable information and the side effect variable information into a pre-constructed vaccine side effect variable learning-based artificial intelligence model; and outputting vaccine side effect prediction and analysis information on the basis of the estimated vaccine side effect classification model and the probability information.

IPC Classes  ?

• G16H 20/10 - ICT specially adapted for therapies or health-improving plans, e.g. for handling prescriptions, for steering therapy or for monitoring patient compliance relating to drugs or medications, e.g. for ensuring correct administration to patients
• G16H 10/60 - ICT specially adapted for the handling or processing of patient-related medical or healthcare data for patient-specific data, e.g. for electronic patient records
• G16H 50/80 - ICT specially adapted for medical diagnosis, medical simulation or medical data miningICT specially adapted for detecting, monitoring or modelling epidemics or pandemics for detecting, monitoring or modelling epidemics or pandemics, e.g. flu
• G06N 20/00 - Machine learning

Abstract

The present disclosure relates to a biomimetic chip for three-dimensionally simulating an endometrium, and an endometrium simulating method using the biomimetic chip. The biomimetic chip according to an embodiment of the present disclosure is a three-dimensional biomimetic chip including a plate, a plurality of chambers, and a plurality of posts, which are arranged between the plurality of chambers, wherein the plurality of chambers include channels in which different cells are cultured, are arranged on the plate to be parallel to each other in one direction, and are arranged adjacent to each other such that at least some sections communicate with each other.

IPC Classes  ?

• C12M 3/00 - Tissue, human, animal or plant cell, or virus culture apparatus
• C12M 3/06 - Tissue, human, animal or plant cell, or virus culture apparatus with filtration, ultrafiltration, inverse osmosis or dialysis means

Abstract

Provided are a composition and a method for promoting differentiation of neural stem cells into dopaminergic neurons, the composition including fusaric acid, ascorbic acid, nicotinamide adenine dinucleotide, or a combination thereof. The composition and method according to an aspect may not only increase differentiation of neural stem cells isolated at an early stage of development into dopaminergic neurons, but also increase differentiation of subcultured neural stem cells into dopaminergic neurons, and thus, it is possible to secure more dopaminergic neurons, and increase therapeutic effects on Parkinson's disease.

IPC Classes  ?

• A61K 35/30 - NervesBrainEyesCorneal cellsCerebrospinal fluidNeuronal stem cellsNeuronal precursor cellsGlial cellsOligodendrocytesSchwann cellsAstrogliaAstrocytesChoroid plexusSpinal cord tissue
• C12N 5/0793 - Neurons

Abstract

Provided is a vector library for yeast two-hybrid screening of a deubiquitinating enzyme that binds to a target protein and a method for identifying a deubiquitinating enzyme binding to a target protein using the same. Further provided is a method for screening an agent having anti-cancer activity targeting the deubiquitinating enzyme USP1, USP7, USP12, or USP49 identified by the identifying method.

IPC Classes  ?

• C40B 30/06 - Methods of screening libraries by measuring effects on living organisms, tissues or cells
• C12N 9/48 - Hydrolases (3.) acting on peptide bonds, e.g. thromboplastin, leucine aminopeptidase (3.4)
• C12N 15/10 - Processes for the isolation, preparation or purification of DNA or RNA
• C12N 15/81 - Vectors or expression systems specially adapted for eukaryotic hosts for fungi for yeasts
• C12Q 1/37 - Measuring or testing processes involving enzymes, nucleic acids or microorganismsCompositions thereforProcesses of preparing such compositions involving hydrolase involving peptidase or proteinase
• C40B 40/02 - Libraries contained in or displayed by microorganisms, e.g. bacteria or animal cellsLibraries contained in or displayed by vectors, e.g. plasmidsLibraries containing only microorganisms or vectors

Abstract

Philadelphus schrenckiiPhiladelphus schrenckii flower extract as an active ingredient.

IPC Classes  ?

• A61K 36/185 - Magnoliopsida (dicotyledons)
• A61P 17/14 - Drugs for dermatological disorders for baldness or alopecia
• A61K 8/9789 - Magnoliopsida [dicotyledons]
• A61Q 7/00 - Preparations for affecting hair growth

Abstract

The present invention relates to a lacrimal gland organoid preparation method. In addition, the present invention relates to: a lacrimal gland organoid prepared by the preparation method; a formulation for preventing or treating dry eye disease, the formulation including the lacrimal gland organoid; and a method for screening a material for preventing or treating dry eye disease using the lacrimal gland organoid. The lacrimal gland organoid prepared according to the present invention has high tissue similarity with human lacrimal gland tissue and excellent tear secretion ability, and in particular, can regenerate damaged lacrimal gland tissue to normalize tear secretion ability when transplanted in vivo. Accordingly, the lacrimal gland organoid preparation method according to the present invention can be used to prepare a lacrimal gland organoid that is similar in shape and function to living tissue, and the prepared lacrimal gland organoid can be used as a material for treating dry eye disease such as Sjogren's syndrome or corneal xerosis or effectively utilized as a method for screening a material for treating dry eye syndrome.

IPC Classes  ?

• C12N 5/071 - Vertebrate cells or tissues, e.g. human cells or tissues
• A61K 35/24 - MucusMucous glandsBursaSynovial fluidArthral fluidExcretaSpinal fluid
• A61P 27/02 - Ophthalmic agents
• G01N 33/50 - Chemical analysis of biological material, e.g. blood, urineTesting involving biospecific ligand binding methodsImmunological testing

Abstract

Provided are an analytical method for providing information necessary for diagnosing recurrent pregnancy loss, comprising measuring an expression level of HtrA4 protein or an expression level of a gene encoding the same in a subject’s sample, and a kit for diagnosing recurrent pregnancy loss, comprising a molecule capable of measuring an expression level of HtrA4 protein or an expression level of a gene encoding the same

IPC Classes  ?

• G01N 33/68 - Chemical analysis of biological material, e.g. blood, urineTesting involving biospecific ligand binding methodsImmunological testing involving proteins, peptides or amino acids
• C12Q 1/6837 - Enzymatic or biochemical coupling of nucleic acids to a solid phase using probe arrays or probe chips
• C12Q 1/6883 - Nucleic acid products used in the analysis of nucleic acids, e.g. primers or probes for diseases caused by alterations of genetic material

Abstract

The present invention provides a pharmaceutical composition comprising neuronal progenitor cells as an active ingredient for prevention or treatment of optic neuropathy. The neural progenitor cells not only exhibit remarkably superior neuroprotective and pro-regenerative effects compared to mesenchymal stem cells (e.g., PSCs) such as placenta-derived stem cells, but also are non-invasive and can be administered by safe sub-Tenon's injection. Accordingly, the pharmaceutical composition of the present invention may be advantageously used as a cell therapy product for treating optic neuropathy.

IPC Classes  ?

• A61K 35/30 - NervesBrainEyesCorneal cellsCerebrospinal fluidNeuronal stem cellsNeuronal precursor cellsGlial cellsOligodendrocytesSchwann cellsAstrogliaAstrocytesChoroid plexusSpinal cord tissue
• A61K 9/00 - Medicinal preparations characterised by special physical form
• A61P 27/02 - Ophthalmic agents

Abstract

The present invention relates to a method for selecting a marker of cellular senescence using machine learning, a biomarker for cellular senescence, and a method for screening a senolytic agent using same. The method for selecting a marker of cellular senescence using machine learning according to one aspect has the effects that more statistically significant genes can be selected by securing a sufficient number of samples by establishing an analysis pipeline for conducting meta-analysis of senescent cell RNA-seq data, and candidates for a senescent cell-specific marker can be found from among various variables through machine learning methodology. In addition, the marker of cellular senescence derived by the method is a more significant gene signature that can specify cellular senescence in a greater variety of types of cells than those of previous studies, and has the effect of not only being useful for specifying or detecting senescent cells, but also being useful for selecting a senolytic agent.

IPC Classes  ?

• G16B 40/20 - Supervised data analysis
• G16B 10/00 - ICT specially adapted for evolutionary bioinformatics, e.g. phylogenetic tree construction or analysis
• G16B 50/00 - ICT programming tools or database systems specially adapted for bioinformatics
• G06N 20/00 - Machine learning

Abstract

According to a composition and a kit for diagnosing ovarian reserve, and a method of providing information for diagnosing ovarian reserve by using the same, according to an aspect, the development of follicles may be predicted early. In addition, by predicting not only the number of oocytes but also the quality of oocytes, a comprehensive diagnosis of ovarian reserve may be made.

IPC Classes  ?

• C12Q 1/6883 - Nucleic acid products used in the analysis of nucleic acids, e.g. primers or probes for diseases caused by alterations of genetic material

Abstract

The disclosure relates to a method of producing bankable and subculturable mature microglia, and according to a method according to an aspect, subculture and banking are possible, and freeze storage and thawing are also possible, and thus, it is possible to simply isolate and use only mature microglia whenever necessary. In addition, it is possible to dramatically reduce the number of subjects required for an experiment, and therefore, the method may contribute economically to all research or industrial fields related to microglia.

IPC Classes  ?

• C12N 5/079 - Neural cells

Abstract

The present invention relates to a biological implant comprising surface-modified zinc and magnesium compounds, and a method for producing same, wherein the biological implant comprises surface-modified zinc and magnesium compounds and thus has improved dispersion stability in a biodegradable polymer phase, can control the release of nitric oxide, and can be improved in terms of biocompatibility, the inhibition of inflammation, and X-ray opacity.

IPC Classes  ?

• A61L 31/12 - Composite materials, i.e. layered or containing one material dispersed in a matrix of the same or different material
• A61L 31/16 - Biologically active materials, e.g. therapeutic substances
• A61L 31/18 - Materials at least partially X-ray or laser opaque
• A61L 31/06 - Macromolecular materials obtained otherwise than by reactions only involving carbon-to-carbon unsaturated bonds
• A61L 17/12 - Homopolymers or copolymers of glycolic or lactic acid
• A61L 17/00 - Materials for surgical sutures or for ligaturing blood vessels
• A61L 27/56 - Porous or cellular materials
• A61L 27/54 - Biologically active materials, e.g. therapeutic substances
• A61L 27/44 - Composite materials, i.e. layered or containing one material dispersed in a matrix of the same or different material having a macromolecular matrix
• A61L 27/18 - Macromolecular materials obtained otherwise than by reactions only involving carbon-to-carbon unsaturated bonds

Abstract

The present invention relates to a method for preparing pluripotent stem cell-derived hematopoietic stem cells and a method for constructing a humanized mouse model by using the prepared hematopoietic stem cells. According to an aspect, the method for preparing hematopoietic stem cells identified an optimal differentiation condition according to a combination of low-molecular-weight compounds and protein growth factors, without gene insertion, and thus can differentiate hematopoietic stem cells from pluripotent stem cells at high yield.

IPC Classes  ?

• C12N 5/0789 - Stem cellsMultipotent progenitor cells
• A01K 67/027 - New or modified breeds of vertebrates

Abstract

The present invention relates to a biomarker for early diagnosis of poor ovarian response, and uses thereof. By using a composition according to one aspect, poor ovarian response can be diagnosed at an early stage, regardless of age, by measuring and comparing the expression level of PGD2, which has significantly low expression in follicular fluid of patients with poor ovarian response. Furthermore, the diagnosis results may be used to establish an individualized treatment strategy for infertile patients, and is expected to ultimately contribute to effective infertility treatment.

IPC Classes  ?

• G01N 33/68 - Chemical analysis of biological material, e.g. blood, urineTesting involving biospecific ligand binding methodsImmunological testing involving proteins, peptides or amino acids
• G01N 33/88 - Chemical analysis of biological material, e.g. blood, urineTesting involving biospecific ligand binding methodsImmunological testing involving prostaglandins

Abstract

The present invention relates to a composition for preventing, treating or ameliorating poor ovarian response syndrome, comprising an RGMc-derived protein. When the composition according to an aspect is used, this may induce the normal development of the ovarian with poor response so as to treat poor ovarian response syndrome and infertility caused thereby, and may effectively recover aged ovarian functions to increase the possibility of pregnancy.

IPC Classes  ?

• A61K 38/17 - Peptides having more than 20 amino acidsGastrinsSomatostatinsMelanotropinsDerivatives thereof from animalsPeptides having more than 20 amino acidsGastrinsSomatostatinsMelanotropinsDerivatives thereof from humans
• A61P 15/08 - Drugs for genital or sexual disordersContraceptives for gonadal disorders or for enhancing fertility, e.g. inducers of ovulation or of spermatogenesis
• A23L 33/17 - Amino acids, peptides or proteins

Abstract

The present invention relates to a method for providing information relating to progression or prognosis of a breast cancer and information for selecting a breast cancer treatment method, the method using a breast cancer MRI. Since genetic information can be predicted by means of a non-invasive MRI when using the method of the present invention, the method may be used to provide information relating to progression or prognosis of a breast cancer or information for selecting a breast cancer treatment method.

IPC Classes  ?

• A61B 5/00 - Measuring for diagnostic purposes Identification of persons
• A61B 5/055 - Detecting, measuring or recording for diagnosis by means of electric currents or magnetic fieldsMeasuring using microwaves or radio waves involving electronic [EMR] or nuclear [NMR] magnetic resonance, e.g. magnetic resonance imaging
• G16B 50/00 - ICT programming tools or database systems specially adapted for bioinformatics
• G16H 30/40 - ICT specially adapted for the handling or processing of medical images for processing medical images, e.g. editing

Abstract

Provided is a pharmaceutical composition for the prevention or treatment of Asherman's syndrome or complications thereof, comprising mitochondria as an active ingredient. The pharmaceutical composition alleviates or treats endometrial adhesion, and can alleviate or treat endometrial fibrosis. Therefore, the pharmaceutical composition can be effectively used in the treatment and prevention of diseases such as endometrial adhesion disease, particularly Asherman's syndrome, and thus is highly industrially applicable.

IPC Classes  ?

• A61K 35/12 - Materials from mammalsCompositions comprising non-specified tissues or cellsCompositions comprising non-embryonic stem cellsGenetically modified cells
• A61K 35/28 - Bone marrowHaematopoietic stem cellsMesenchymal stem cells of any origin, e.g. adipose-derived stem cells
• A61P 15/02 - Drugs for genital or sexual disordersContraceptives for disorders of the vagina
• A61P 15/08 - Drugs for genital or sexual disordersContraceptives for gonadal disorders or for enhancing fertility, e.g. inducers of ovulation or of spermatogenesis

Abstract

The present invention relates to a biomimetic nerve chip for evaluating the efficacy and toxicity of a drug, a method for evaluating the efficacy of a drug on nerve cells through astrocytes by using the biomimetic nerve chip, and a method for evaluating the toxicity of a drug on nerve cells through astrocytes by using the biomimetic nerve chip, the biomimetic nerve chip comprising: an astrocyte supply unit and a nerve cell supply unit for simulating nerve tissue; and a culture solution supply unit for supplying a culture solution to the astrocyte supply unit and the nerve cell supply unit. By using the biomimetic nerve chip for evaluating the efficacy and toxicity of a drug provided in the present invention, it is possible to overcome inaccuracies due to differences between the different species in animal experiments in the study of nerve tissues, and using a combination of astrocytes and nerve cells enables use of the nerve chip as a platform to more accurately evaluate the efficacy and toxicity of a drug under conditions similar to in vivo conditions, and the nerve chip can be applied to studies of microenvironments in nerve tissues and other organ-on-a-chip studies. Therefore, the present invention may be utilized in the development of a human-on-a-chip that can effectively analyze the efficacy and toxicity of a drug.

IPC Classes  ?

• G01N 33/50 - Chemical analysis of biological material, e.g. blood, urineTesting involving biospecific ligand binding methodsImmunological testing
• C12N 5/079 - Neural cells
• C12N 5/0793 - Neurons
• C12M 3/06 - Tissue, human, animal or plant cell, or virus culture apparatus with filtration, ultrafiltration, inverse osmosis or dialysis means
• C12M 1/00 - Apparatus for enzymology or microbiology
• C12M 1/34 - Measuring or testing with condition measuring or sensing means, e.g. colony counters

Abstract

A composition may increase a rate of endometrial blood flow and a composition for increasing implantation potential, including botulinum toxin or a salt thereof, and a pharmaceutical composition may preventing or treating subfertility or infertility, including botulinum toxin or a pharmaceutically acceptable salt thereof. Such compositions can increase a rate of endometrial blood flow and improve embryonic implantation potential just by being applied to the endometrium, and thus may be helpful to patients with subfertility or infertility, especially those who have repetitive failures in embryonic implantation. Since the compositions include botulinum toxin which is a substance that has been widely applied to the human body for cosmetic purposes, studies on human toxicity may have a shortened period, and thus the disclosure is very useful in economical and industrial aspects.

IPC Classes  ?

• A61K 38/48 - Hydrolases (3) acting on peptide bonds (3.4)
• A61P 15/08 - Drugs for genital or sexual disordersContraceptives for gonadal disorders or for enhancing fertility, e.g. inducers of ovulation or of spermatogenesis

Abstract

The present invention relates to: a method for providing information for choosing a breast cancer treatment method by using a breast cancer ultrasonic image and gene information; a system for choosing a breast cancer treatment method by using a breast cancer ultrasonic image; and a method for providing information required for predicting the prognosis of a breast cancer patient.

IPC Classes  ?

• A61B 8/08 - Clinical applications

Abstract

The present invention relates to a pharmaceutical composition for preventing or treating a stroke, comprising, as an active ingredient, neural precursor cells differentiated from human induced pluripotent stem cells (hiPSC-NPCs) comprising HLA homozygotes, wherein, through the use of a homozygous type, immunorejection can be eliminated and stable stroke treatment effects can be exhibited.

IPC Classes  ?

• A61K 35/30 - NervesBrainEyesCorneal cellsCerebrospinal fluidNeuronal stem cellsNeuronal precursor cellsGlial cellsOligodendrocytesSchwann cellsAstrogliaAstrocytesChoroid plexusSpinal cord tissue
• A61P 9/10 - Drugs for disorders of the cardiovascular system for treating ischaemic or atherosclerotic diseases, e.g. antianginal drugs, coronary vasodilators, drugs for myocardial infarction, retinopathy, cerebrovascula insufficiency, renal arteriosclerosis
• C12N 5/0793 - Neurons

Abstract

The present invention relates to a use of neogenin as a marker for diagnosing brain damage induced by epilepsy. Since truncated neogenin increases when brain damage is induced by epilepsy, a composition according to the present invention can be used to easily and quickly diagnose the brain damage induced by epilepsy, and can be utilized as a target for developing a therapeutic agent for diseases caused by brain damage.

IPC Classes  ?

• G01N 33/68 - Chemical analysis of biological material, e.g. blood, urineTesting involving biospecific ligand binding methodsImmunological testing involving proteins, peptides or amino acids
• G01N 33/558 - ImmunoassayBiospecific binding assayMaterials therefor using diffusion or migration of antigen or antibody
• A61K 31/221 - Esters, e.g. nitroglycerine, selenocyanates of carboxylic acids of acyclic acids, e.g. pravastatin with compounds having an amino group, e.g. acetylcholine, acetylcarnitine
• A61P 25/00 - Drugs for disorders of the nervous system
• A61P 25/08 - AntiepilepticsAnticonvulsants

Abstract

The present invention provides a cephalothin derivative or a pharmaceutically acceptable salt thereof, a preparation method therefor, and a composition for preventing hair loss or promoting hair growth, comprising same

IPC Classes  ?

• C07D 501/57 - 7-Acylaminocephalosporanic or substituted 7-acylaminocephalosporanic acids in which the acyl radicals are derived from carboxylic acids with a further substituent in position 7, e.g. cephamycines
• C07D 501/02 - Preparation
• A61K 31/546 - Compounds containing 5-thia-1-azabicyclo [4.2.0] octane ring systems, i.e. compounds containing a ring system of the formula , e.g. cephalosporins, cefaclor, cephalexine containing further heterocyclic rings, e.g. cephalothin
• A61P 17/14 - Drugs for dermatological disorders for baldness or alopecia
• A61K 8/49 - Cosmetics or similar toiletry preparations characterised by the composition containing organic compounds containing heterocyclic compounds
• A61Q 7/00 - Preparations for affecting hair growth

Abstract

The present invention relates to a biodegradable polymer support containing a bioactive material and manufacturing method therefor, wherein the biodegradable polymer support suppresses inflammatory reactions caused by acidic materials generated in a decomposition process, facilitates a mechanical strength control, and includes a cell-derived bioactive material of a target tissue and a bioactive material, and thus, can induce tissue regeneration more effectively.

IPC Classes  ?

• A61L 27/56 - Porous or cellular materials
• A61L 27/44 - Composite materials, i.e. layered or containing one material dispersed in a matrix of the same or different material having a macromolecular matrix
• A61L 27/36 - Materials for prostheses or for coating prostheses containing ingredients of undetermined constitution or reaction products thereof
• A61L 27/54 - Biologically active materials, e.g. therapeutic substances
• A61L 27/58 - Materials at least partially resorbable by the body
• A61L 31/14 - Materials characterised by their function or physical properties
• A61L 31/12 - Composite materials, i.e. layered or containing one material dispersed in a matrix of the same or different material
• A61L 31/16 - Biologically active materials, e.g. therapeutic substances
• A61L 31/00 - Materials for other surgical articles

Abstract

Provided are a composition and a kit, each for culturing natural killer cells, and a method of using the same. According to the composition for culturing natural killer cells according to aspect, and a method of culturing natural killer cells using the same, when natural killer cells are cultured in peripheral blood mononuclear cells, they are cultured in a medium including the composition for culturing natural killer cells, the composition including magnetic particles, of which at least one surface is bound with an activating receptor ligand, an inhibitory receptor ligand, a costimulatory receptor ligand, a cytokine, a cytokine receptor, an immune checkpoint ligand, a blocking antibody, or a combination thereof, thereby proliferating natural killer cells in a large quantity and promoting activation or inhibition of natural killer cells, or expansion of natural killer cells. Accordingly, the natural killer cells cultured using the same may be usefully applied to immune cell therapy products. Further, the magnetic particles may be easily separated from the medium, which is a simple and economical manner. Since the safe magnetic particles are used, they are excellent in terms of clinical safety.

IPC Classes  ?

• C12N 5/0783 - T cellsNK cellsProgenitors of T or NK cells

Abstract

The present invention relates to a biomarker for predicting the risk of developing a food allergy and a use thereof. The composition according to one aspect of the present invention can simply and accurately predict the risk of developing a food allergy on the basis of serum lipopolysaccharide-binding protein (LBP) levels. Particularly, since the risk of developing a food allergy can be predicted in advance for a subject who does not have any symptoms of the food allergy, the present invention is expected to be useful not only for the effective prevention and management of the food allergy, but also for the establishment of a personalized course of treatment.

IPC Classes  ?

• C12Q 1/6883 - Nucleic acid products used in the analysis of nucleic acids, e.g. primers or probes for diseases caused by alterations of genetic material
• G01N 33/68 - Chemical analysis of biological material, e.g. blood, urineTesting involving biospecific ligand binding methodsImmunological testing involving proteins, peptides or amino acids

Abstract

A composition according to the present disclosure may be very effectively used not only to prevent, ameliorate or treat cancer, but also to inhibit metastasis of cancer, by inhibiting the growth of cancer cells and very effectively inhibiting the metastasis of cancer cells to other tissues.

IPC Classes  ?

• A61K 31/136 - Amines, e.g. amantadine having aromatic rings, e.g. methadone having the amino group directly attached to the aromatic ring, e.g. benzeneamine
• A61K 31/18 - Sulfonamides
• A61K 31/4453 - Non-condensed piperidines, e.g. piperocaine only substituted in position 1, e.g. propipocaine, diperodon
• A61K 31/495 - Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with two nitrogen atoms as the only ring hetero atoms, e.g. piperazine
• A61K 45/06 - Mixtures of active ingredients without chemical characterisation, e.g. antiphlogistics and cardiaca
• A61P 35/00 - Antineoplastic agents

Abstract

The present invention provides a selective fluorescence-staining method for oocytes, the method comprising culturing ex vivo separated oocytes in a medium containing tetramethylrhodamine isothiocyanate, cyanine 3 carboxylic acid, or cyanine 5 carboxylic acid as a fluorescence probe.

IPC Classes  ?

• C12Q 1/04 - Determining presence or kind of microorganismUse of selective media for testing antibiotics or bacteriocidesCompositions containing a chemical indicator therefor
• C12N 5/071 - Vertebrate cells or tissues, e.g. human cells or tissues

Abstract

The present invention provides an Oct-3/4 protein variant wherein lysine at position 156; lysine at position 286; or lysines at positions 156 and 286 in the Oct-3/4 protein is (are) substituted with arginine. The Oct-3/4 protein variant according to the present invention can inhibit a protein degradation mechanism through ubiquitination, and shows a higher half-life, compared to the wild-type Oct-3/4, thereby exhibiting high stability.

IPC Classes  ?

• C07K 14/47 - Peptides having more than 20 amino acidsGastrinsSomatostatinsMelanotropinsDerivatives thereof from animalsPeptides having more than 20 amino acidsGastrinsSomatostatinsMelanotropinsDerivatives thereof from humans from vertebrates from mammals

Abstract

An aspect provides: a physiologically-based pharmacokinetic core model which can be commonly applied to two or more compounds that share the same parent nucleus; and a method for constructing the physiologically-based pharmacokinetic core model. According to the physiologically-based pharmacokinetic core model and the method for constructing the physiologically-based pharmacokinetic core model, there is the effect of conducting exposure assessment simply only by deriving the distribution coefficient, without constructing a separate PBPK model for each individual compound.

IPC Classes  ?

• G16C 20/50 - Molecular design, e.g. of drugs
• G16C 20/10 - Analysis or design of chemical reactions, syntheses or processes
• G16C 20/30 - Prediction of properties of chemical compounds, compositions or mixtures
• G16C 60/00 - Computational materials science, i.e. ICT specially adapted for investigating the physical or chemical properties of materials or phenomena associated with their design, synthesis, processing, characterisation or utilisation

Abstract

A composition according to one embodiment, comprising a cationic substance as an active ingredient, increases the stability of perforin proteins, thus induces the accumulation of perforin proteins in cells, increasing the activity of immunocytes.

IPC Classes  ?

• A61K 31/785 - Polymers containing nitrogen
• A61P 37/00 - Drugs for immunological or allergic disorders
• C12N 5/0783 - T cellsNK cellsProgenitors of T or NK cells
• A61K 35/17 - LymphocytesB-cellsT-cellsNatural killer cellsInterferon-activated or cytokine-activated lymphocytes

Abstract

The present invention relates to a method for providing DNA genetic information using breast cancer ultrasound images. When the method for providing DNA genetic information using breast cancer ultrasound images according to the present invention is used, information that is helpful in determining a treatment and a prognosis for breast cancer can be provided via a noninvasive method.

IPC Classes  ?

• C12Q 1/6886 - Nucleic acid products used in the analysis of nucleic acids, e.g. primers or probes for diseases caused by alterations of genetic material for cancer
• A61B 8/08 - Clinical applications
• G16B 40/20 - Supervised data analysis
• G16H 50/70 - ICT specially adapted for medical diagnosis, medical simulation or medical data miningICT specially adapted for detecting, monitoring or modelling epidemics or pandemics for mining of medical data, e.g. analysing previous cases of other patients
• G16H 50/50 - ICT specially adapted for medical diagnosis, medical simulation or medical data miningICT specially adapted for detecting, monitoring or modelling epidemics or pandemics for simulation or modelling of medical disorders

Abstract

Provided are a composition and a kit for differentiation of stem cells into neural crest stem cells (NCSCs), each including a transforming growth factor beta (TGF-β) I receptor inhibitor and 0.001 μM to 2.5 μM of a bone morphogenetic protein (BMP) inhibitor, and a method using the same. Accordingly, stem cells may be efficiently differentiated into neural crest stem cells using the simple, low-cost composition.

IPC Classes  ?

• C12N 5/0797 - Stem cellsProgenitor cells

Abstract

The present invention relates to a cell therapy product comprising embryonic stem cell-derived mesenchymal stem cells as an active ingredient for treatment of stroke. According to the present invention, administration of embryonic stem cell-derived mesenchymal stem cells and EPO in combination to a stroke patient can be expected to bring about recovery from cranial nerve injury and effective alleviation in stroke-induced conductor disorder.

IPC Classes  ?

• A61K 35/28 - Bone marrowHaematopoietic stem cellsMesenchymal stem cells of any origin, e.g. adipose-derived stem cells
• A61K 38/18 - Growth factorsGrowth regulators
• A61K 9/00 - Medicinal preparations characterised by special physical form
• A61P 9/10 - Drugs for disorders of the cardiovascular system for treating ischaemic or atherosclerotic diseases, e.g. antianginal drugs, coronary vasodilators, drugs for myocardial infarction, retinopathy, cerebrovascula insufficiency, renal arteriosclerosis

Abstract

Provided is an analytical method for providing information necessary for a diagnosis of urolithiasis, including measuring an expression level of a gene encoding a YOD1, USP6, USP19, PSMD14, or USP26 protein in a biological sample from a subject to be diagnosed; and a kit for a diagnosis of urolithiasis which is used in the analytical method.

IPC Classes  ?

• C12Q 1/6883 - Nucleic acid products used in the analysis of nucleic acids, e.g. primers or probes for diseases caused by alterations of genetic material
• C12Q 1/686 - Polymerase chain reaction [PCR]

Abstract

The present invention relates to a composition and method for promoting the differentiation of neural stem cells into dopaminergic neurons, the composition including fusaric acid, ascorbic acid, nicotinamide adenine dinucleotide, or a combination thereof. The composition and method according to an aspect not only increase the differentiation of neural stem cells, isolated in an initial stage of development, into dopaminergic neurons, but also increase the differentiation of subcultured neural stem cells into dopaminergic neurons, thus making it possible to secure more dopaminergic neurons and therefore increase therapeutic effects on Parkinson's disease.

IPC Classes  ?

• C12N 5/0793 - Neurons
• A61K 35/30 - NervesBrainEyesCorneal cellsCerebrospinal fluidNeuronal stem cellsNeuronal precursor cellsGlial cellsOligodendrocytesSchwann cellsAstrogliaAstrocytesChoroid plexusSpinal cord tissue
• A61P 25/16 - Anti-Parkinson drugs

Abstract

Provided is a composition for inhibiting, preventing, alleviating, or treating adipogenesis. Mesenchymal stem cells according to one aspect or a composition comprising the same inhibit fat accumulation or adipose tissue increase and thus may be advantageously utilized in the prevention, treatment, or alleviation of diseases associated with abnormal fat metabolism.

IPC Classes  ?

• C12N 5/0775 - Mesenchymal stem cellsAdipose-tissue derived stem cells
• A61K 35/28 - Bone marrowHaematopoietic stem cellsMesenchymal stem cells of any origin, e.g. adipose-derived stem cells
• C12N 9/16 - Hydrolases (3.) acting on ester bonds (3.1)

Abstract

The present invention provides an analysis method, comprising the step of measuring the expression level of PGK1, or the expression level of a gene encoding same, in a sample from a subject, in order to provide information required for diagnosis of recurrent miscarriage. In addition, the present invention provides a kit for diagnosis of recurrent miscarriage, comprising a molecule capable of measuring the expression level of PGK1 or the expression level of a gene encoding same.

IPC Classes  ?

• G01N 33/68 - Chemical analysis of biological material, e.g. blood, urineTesting involving biospecific ligand binding methodsImmunological testing involving proteins, peptides or amino acids
• C12Q 1/6883 - Nucleic acid products used in the analysis of nucleic acids, e.g. primers or probes for diseases caused by alterations of genetic material

Abstract

Provided is a biomarker for diagnosing or predicting reactivity of an ovary to FSH and use thereof. According to a composition or a kit for diagnosing or predicting reactivity of an ovary to FSH and a method using the same according to one aspect, the degree of reactivity of the ovary may be easily diagnosed using miRNA present in blood, follicular fluid, granulosa cells, and cumulus cells, and thus it is easy to predict or diagnose symptoms or diseases caused by abnormal reactivity of the ovary to FSH.

IPC Classes  ?

• C12Q 1/6883 - Nucleic acid products used in the analysis of nucleic acids, e.g. primers or probes for diseases caused by alterations of genetic material

Abstract

The present invention relates to a biomimetic chip for simulating the endometrium in three dimensions, and an endometrium simulating method using same. The three-dimensional biomimetic chip for simulating the endometrium according to an embodiment of the present invention comprises: a plate; a plurality of chambers; and a plurality of posts disposed between the plurality of chambers, wherein the plurality of chambers include channels which are provided therein and in which different cells are cultured, and the plurality of chambers are disposed on the plate in parallel with each other in one direction and disposed adjacent to each other such that at least some sections thereof are in communication with each other.

IPC Classes  ?

• C12M 3/00 - Tissue, human, animal or plant cell, or virus culture apparatus
• C12M 3/06 - Tissue, human, animal or plant cell, or virus culture apparatus with filtration, ultrafiltration, inverse osmosis or dialysis means
• C12M 1/00 - Apparatus for enzymology or microbiology
• C12N 5/071 - Vertebrate cells or tissues, e.g. human cells or tissues

Abstract

Provided are a composition and a kit for differentiation of stem cells into neural progenitor cells (NPCs), each including a protein kinase C (PKC) inhibitor and a bone morphogenic protein (BMP) inhibitor, and a method using the same. Accordingly, stem cells may be efficiently differentiated into neural progenitor cells using a simple, low-cost composition.

IPC Classes  ?

• C12N 5/0793 - Neurons

Abstract

The present invention pertains to an anticancer composition containing IF1 (ATPase inhibitory factor 1). The IF1 (ATPase inhibitory factor 1) according to the present invention has the effect of releasing extracellular ATP, induces cytotoxicity in various cancer cells and exhibits anticancer efficacy, and is thus very useful as an active ingredient of a powerful anticancer agent.

IPC Classes  ?

• A61K 38/17 - Peptides having more than 20 amino acidsGastrinsSomatostatinsMelanotropinsDerivatives thereof from animalsPeptides having more than 20 amino acidsGastrinsSomatostatinsMelanotropinsDerivatives thereof from humans
• A23L 33/17 - Amino acids, peptides or proteins
• A61P 35/00 - Antineoplastic agents

Abstract

Provided is an analytical method for providing information necessary for a diagnosis of alcohol use disorder, including measuring (i) an expression level of a gene encoding a JNK or p-JNK protein in a subject's sample, (ii) an expression level of a gene encoding a JNK or p-JNK protein and an expression level of a gene encoding the Elk-1 protein in a subject's sample, or (iii) expression levels of genes encoding JNK, p-JNK, and Elk-1 proteins in a subject's sample, respectively; and a kit for a diagnosis of alcohol use disorder which is used in the analytical method.

IPC Classes  ?

• C12Q 1/6883 - Nucleic acid products used in the analysis of nucleic acids, e.g. primers or probes for diseases caused by alterations of genetic material
• G01N 33/68 - Chemical analysis of biological material, e.g. blood, urineTesting involving biospecific ligand binding methodsImmunological testing involving proteins, peptides or amino acids

Abstract

The present invention relates to a method for producing bankable and subculturable mature microglia. According to the method, according to one aspect, microglia may be subcultured and stocked, and also frozen and thawed, and thus only mature microglia may be conveniently isolated and used every time when needed. In addition, the amount of entities needed for experiments may be remarkably reduced, and thus the present invention may also economically contribute to all microglia-related research or industrial fields.

IPC Classes  ?

• C12N 5/079 - Neural cells

Abstract

The present invention provides an analysis method comprising the step of measuring the expression level of HtrA4 protein or the expression level of a gene encoding same in a sample from a subject in order to provide information necessary for the diagnosis of recurrent miscarriage. In addition, the present invention provides a kit for diagnosing recurrent miscarriage, comprising a molecule capable of measuring the expression level of HtrA4 protein or the expression level of a gene encoding same.

IPC Classes  ?

• G01N 33/68 - Chemical analysis of biological material, e.g. blood, urineTesting involving biospecific ligand binding methodsImmunological testing involving proteins, peptides or amino acids
• G01N 33/53 - ImmunoassayBiospecific binding assayMaterials therefor
• C12Q 1/6883 - Nucleic acid products used in the analysis of nucleic acids, e.g. primers or probes for diseases caused by alterations of genetic material
• C12Q 1/6837 - Enzymatic or biochemical coupling of nucleic acids to a solid phase using probe arrays or probe chips

Abstract

According to one embodiment of a composition and kit for diagnosing ovarian reserve and a method for providing information for diagnosing ovarian reserve using the composition and kit, early stage follicular development can be predicted. Moreover, not only only the number of eggs but quality thereof can be predicted, thus allowing a comprehensive ovarian reserve diagnosis.

IPC Classes  ?

• C12Q 1/6883 - Nucleic acid products used in the analysis of nucleic acids, e.g. primers or probes for diseases caused by alterations of genetic material

Abstract

The present invention relates to a pseudogene biomarker for diagnosis and/or prognosis prediction of glioma, and provided are a composition for diagnosis and/or prognosis prediction of glioma comprising a formulation for detecting the biomarker, a kit for diagnosis and/or prognosis prediction of glioma comprising the composition, and a method for providing information required for diagnosis and/or prognosis prediction of glioma by using the biomarker. The pseudogene biomarker can clearly diagnose the grade of glioma as grade 2 to grade 4, and the prognosis can be predicted according to the difference in expression level, thereby enabling accurate diagnosis and/or prediction of the glioma.

IPC Classes  ?

• C12Q 1/6886 - Nucleic acid products used in the analysis of nucleic acids, e.g. primers or probes for diseases caused by alterations of genetic material for cancer

Abstract

The present invention relates to a biomimetic nerve chip for evaluating the efficacy and toxicity of a drug, a method for evaluating the efficacy of a drug on nerve cells through astrocytes by using the biomimetic nerve chip, and a method for evaluating the toxicity of a drug on nerve cells through astrocytes by using the biomimetic nerve chip, the biomimetic nerve chip comprising: an astrocyte supply unit and a nerve cell supply unit for simulating nerve tissue; and a culture solution supply unit for supplying a culture solution to the astrocyte supply unit and the nerve cell supply unit. By using the biomimetic nerve chip for evaluating the efficacy and toxicity of a drug provided in the present invention, it is possible to overcome inaccuracies due to differences between the different species in animal experiments in the study of nerve tissues, and using a combination of astrocytes and nerve cells enables use of the nerve chip as a platform to more accurately evaluate the efficacy and toxicity of a drug under conditions similar to in vivo conditions, and the nerve chip can be applied to studies of microenvironments in nerve tissues and other organ-on-a-chip studies. Therefore, the present invention may be utilized in the development of a human-on-a-chip that can effectively analyze the efficacy and toxicity of a drug.

IPC Classes  ?

• G01N 33/50 - Chemical analysis of biological material, e.g. blood, urineTesting involving biospecific ligand binding methodsImmunological testing
• C12M 3/06 - Tissue, human, animal or plant cell, or virus culture apparatus with filtration, ultrafiltration, inverse osmosis or dialysis means
• C12M 1/00 - Apparatus for enzymology or microbiology
• B01L 3/00 - Containers or dishes for laboratory use, e.g. laboratory glasswareDroppers
• C12N 5/0793 - Neurons
• C12N 5/079 - Neural cells

Abstract

Provided are: a pharmaceutical composition, food composition or cosmetic composition for preventing, alleviating or treating skin photoaging, or for whitening, comprising, as an active ingredient, racemic DHPV being useful as a photoaging inhibitor, or enantiomers thereof; a method for preventing, alleviating or treating skin photoaging, or for whitening, administering the active ingredient; and a method for preparing the enantiomers.

IPC Classes  ?

• A61K 31/365 - Lactones
• A61P 17/00 - Drugs for dermatological disorders
• A61P 17/16 - Emollients or protectives, e.g. against radiation
• A61K 8/49 - Cosmetics or similar toiletry preparations characterised by the composition containing organic compounds containing heterocyclic compounds
• A61Q 19/02 - Preparations for care of the skin for chemically bleaching or whitening the skin
• A61Q 19/08 - Anti-ageing preparations
• A61Q 17/04 - Topical preparations for affording protection against sunlight or other radiationTopical sun tanning preparations
• C07D 307/33 - Oxygen atoms in position 2, the oxygen atom being in its keto or unsubstituted enol form

Abstract

According to an anticancer therapy-aiding composition including a liposome composition and a drug delivery method according to an aspect, the efficiency of delivering an immunologic adjuvant into immune cells is improved, thus increasing immune system activity. As a result, the cancer treatment effect can be enhanced in patients having various forms of cancer.

IPC Classes  ?

• A61K 39/39 - Medicinal preparations containing antigens or antibodies characterised by the immunostimulating additives, e.g. chemical adjuvants
• A61K 9/127 - Synthetic bilayered vehicles, e.g. liposomes or liposomes with cholesterol as the only non-phosphatidyl surfactant
• A61P 35/00 - Antineoplastic agents
• A61K 39/00 - Medicinal preparations containing antigens or antibodies

Abstract

The present invention pertains to: a cardiac perimysium-level biomimetic heart-on-a-chip which is used for testing the cardiac efficacy and toxicity of drugs, and includes a culture solution supply part for supplying a culture solution to cardiomyocytes, a hydrogel supply part for mimicking cardiac perimysium, and a cardiomyocyte supply part containing fixed cardiomyocytes; a method for evaluating the efficacy of drugs on cardiomyocytes by using the heart-on-a-chip; and a method for evaluating the toxicity of drugs on cardiomyocytes by using the heart-on-a-chip. A cardiac perimysium mimetic heart-on-a-chip for evaluating the efficacy and toxicity of drugs according to the present invention can be used to correct inaccuracies caused by interspecies differences in animal experiments for cardiac research, can be used as a platform for more accurately evaluating the efficacy and toxicity of drugs under in vivo-like conditions by using cardiomyocytes alone or together with hepatocytes, and can be applied to research on intracardiac microenvironments and research on other types of organs-on-chips. Thus, it will be possible to utilize the present invention in the development of a human-on-a-chip that can effectively analyze the effectiveness and toxicity of drugs.

IPC Classes  ?

• C12M 3/06 - Tissue, human, animal or plant cell, or virus culture apparatus with filtration, ultrafiltration, inverse osmosis or dialysis means
• C12M 3/00 - Tissue, human, animal or plant cell, or virus culture apparatus
• C12M 1/00 - Apparatus for enzymology or microbiology
• C12N 5/077 - Mesenchymal cells, e.g. bone cells, cartilage cells, marrow stromal cells, fat cells or muscle cells
• G01N 33/50 - Chemical analysis of biological material, e.g. blood, urineTesting involving biospecific ligand binding methodsImmunological testing

Abstract

The present invention relates to a composition comprising Botulinium toxin or a salt thereof for increasing an endometrial blood flow rate, a composition for improving an implantation potential, and a pharmaceutical composition comprising Botulinium toxin or a pharmaceutically acceptable salt thereof for prevention or treatment of substerility or infertility. Even when being just applied to the endometrium, the compositions can improve an embryonic implantation potential as well as inducing an increase of endometrial blood flow rate. Thus, the compositions are helpful for patients with substerility or infertility, especially patients who suffer from repeated failure in embryonic implantation. Furthermore, a period of study into human toxicity can be reduced because the compositions contain Botulinium toxin, which is a material that has been widely applied to the human body for beauty purposes. Thus, the present invention is very advantageous in terms of economic and industrial aspects.

IPC Classes  ?

• A61K 38/48 - Hydrolases (3) acting on peptide bonds (3.4)
• A61P 15/08 - Drugs for genital or sexual disordersContraceptives for gonadal disorders or for enhancing fertility, e.g. inducers of ovulation or of spermatogenesis

Abstract

The present invention relates to: a method for providing information for choosing a breast cancer treatment method by using a breast cancer ultrasonic image and gene information; a system for choosing a breast cancer treatment method by using a breast cancer ultrasonic image; and a method for providing information required for predicting the prognosis of a breast cancer patient.

IPC Classes  ?

• G16H 30/20 - ICT specially adapted for the handling or processing of medical images for handling medical images, e.g. DICOM, HL7 or PACS
• G16H 50/20 - ICT specially adapted for medical diagnosis, medical simulation or medical data miningICT specially adapted for detecting, monitoring or modelling epidemics or pandemics for computer-aided diagnosis, e.g. based on medical expert systems
• G16H 20/00 - ICT specially adapted for therapies or health-improving plans, e.g. for handling prescriptions, for steering therapy or for monitoring patient compliance
• G16B 25/10 - Gene or protein expression profilingExpression-ratio estimation or normalisation
• A61B 8/08 - Clinical applications
• A61B 34/10 - Computer-aided planning, simulation or modelling of surgical operations

Abstract

The present invention relates to nanoparticles for immunotherapy and to a pharmaceutical composition comprising NK cells and the nanoparticles. According to one aspect, by means of the nanoparticles, a gene can be delivered to and expressed in immune cells, and the NK cells having the nanoparticles incorporated therein can effectively treat cancer without adverse side effects of existing CAR T cells and enable cell tracking at the same time.

IPC Classes  ?

• A61K 9/51 - Nanocapsules
• A61K 31/7088 - Compounds having three or more nucleosides or nucleotides
• A61K 45/06 - Mixtures of active ingredients without chemical characterisation, e.g. antiphlogistics and cardiaca
• A61K 39/00 - Medicinal preparations containing antigens or antibodies
• A61P 35/00 - Antineoplastic agents

Abstract

The present invention relates to a biomedical implant comprising surface-modified inorganic particles and a biodegradable polymer, and a preparation method therefor. The inorganic particles according to an aspect neutralize acidic lysates generated upon the degradation of the biodegradable polymer to inhibit cellular inflammatory response, reactive oxygen species, apoptosis, necrosis, and senescence caused by the acidification, thereby improving the biocompatibility of the biomedical implant. After growth of monomers on the surface, the polymer is secondarily subjected to surface modification with hydrophobic polymers having various molecular weights so that the modification content increases. The hydrophobic polymers on the surface can lead to high dispersion stability in organic solvents.

IPC Classes  ?

• A61L 31/12 - Composite materials, i.e. layered or containing one material dispersed in a matrix of the same or different material
• A61L 31/14 - Materials characterised by their function or physical properties
• A61L 31/08 - Materials for coatings
• A61L 31/16 - Biologically active materials, e.g. therapeutic substances
• A61F 2/82 - Devices providing patency to, or preventing collapsing of, tubular structures of the body, e.g. stents
• A61F 2/00 - Filters implantable into blood vesselsProstheses, i.e. artificial substitutes or replacements for parts of the bodyAppliances for connecting them with the bodyDevices providing patency to, or preventing collapsing of, tubular structures of the body, e.g. stents
• A61L 27/44 - Composite materials, i.e. layered or containing one material dispersed in a matrix of the same or different material having a macromolecular matrix
• A61L 27/58 - Materials at least partially resorbable by the body
• A61L 27/56 - Porous or cellular materials

Abstract

A method for increasing dendritic cell migration ability, and a use thereof are disclosed. A method according to one aspect can increase the migration ability of mature dendritic cells and increase the induction, by dendritic cells, of inflammatory cytokine production, T lymphocyte proliferation and T lymphocyte polarization, and thus can be used for the prevention or treatment of immune-related diseases.

IPC Classes  ?

• C12N 5/0784 - Dendritic cellsProgenitors thereof
• A61K 35/15 - Cells of the myeloid line, e.g. granulocytes, basophils, eosinophils, neutrophils, leucocytes, monocytes, macrophages or mast cellsMyeloid precursor cellsAntigen-presenting cells, e.g. dendritic cells

Abstract

The present invention pertains to: an endomyocardial level biomimetic heart-on-a-chip which is used for testing the cardiac efficacy and toxicity of drugs, and includes a culture solution supply unit for supplying a culture solution to cardiomyocytes, and a cardiomyocyte supply unit containing fixed cardiomyocytes; a method for evaluating the efficacy of drugs on cardiomyocytes by using the heart-on-a-chip; and a method for evaluating the toxicity of drugs on cardiomyocytes by using the heart-on-a-chip. An endomyocardial mimetic heart-on-a-chip for evaluating the efficacy and toxicity of drugs according to the present invention can be used to correct inaccuracies in animal experiments for cardiac research caused by interspecies differences, can be used as a platform for more accurately evaluating the efficacy and toxicity of drugs under in vivo-like conditions by using cardiomyocytes alone or together with hepatocytes, and can be applied to research on intracardiac microenvironments and other types of research on organs-on-chips. Thus, it will be possible to utilize the present invention in the development of a human-on-a-chip that can effectively analyze the effectiveness and toxicity of drugs.

IPC Classes  ?

• C12M 3/06 - Tissue, human, animal or plant cell, or virus culture apparatus with filtration, ultrafiltration, inverse osmosis or dialysis means
• C12M 1/12 - Apparatus for enzymology or microbiology with sterilisation, filtration, or dialysis means
• C12N 5/077 - Mesenchymal cells, e.g. bone cells, cartilage cells, marrow stromal cells, fat cells or muscle cells
• G01N 33/50 - Chemical analysis of biological material, e.g. blood, urineTesting involving biospecific ligand binding methodsImmunological testing
• B01L 3/00 - Containers or dishes for laboratory use, e.g. laboratory glasswareDroppers

Abstract

An aspect provides a method of increasing efficiency of somatic cell nuclear transfer using a substance (RS-1) increasing Rad51 activity, and a somatic cell nuclear transfer cell prepared according to the method. Another aspect provides a method of screening for a substance increasing Rad51 activity to increase efficiency of somatic cell nuclear transfer. When the substance increasing Rad51 activity is used, efficiency of somatic cell nuclear transfer may be increased.

IPC Classes  ?

• C12N 5/0735 - Embryonic stem cellsEmbryonic germ cells
• C12N 5/073 - Embryonic cells or tissuesFoetal cells or tissues
• A61D 19/04 - Instruments or methods for reproduction or fertilisation for embryo transplantation

Abstract

The present disclosure relates to a novel method for synthesizing DHPV, and more particularly, to a novel method for synthesizing DHPV (5-(3′,4′-dihydroxyphenyl)-γ-valerolactone)) which is a major metabolite of cacao. This method has the advantage of not only facilitating a large-scale synthesis by a new synthesis method that can overcome existing defects, but also making it easy to select antioxidants and isomers exhibiting anti-aging bioactivities. Therefore, it is effective in enabling mass production of DHPV having high value as a functional material for cosmetics and pharmaceuticals in a simple and economical manner.

IPC Classes  ?

• C07D 307/33 - Oxygen atoms in position 2, the oxygen atom being in its keto or unsubstituted enol form

Abstract

The present invention provides a vector library for yeast two-hybrid screening of a deubiquitinating enzyme that binds to a target protein and a method for identifying a deubiquitinating enzyme binding to a target protein using the same. Also, the present invention provides a method for screening an agent having anti-cancer activity targeting the deubiquitinating enzyme USP1, USP7, USP12, or USP49 identified by said identifying method.

IPC Classes  ?

• C40B 30/06 - Methods of screening libraries by measuring effects on living organisms, tissues or cells
• C12N 9/48 - Hydrolases (3.) acting on peptide bonds, e.g. thromboplastin, leucine aminopeptidase (3.4)
• C12N 15/10 - Processes for the isolation, preparation or purification of DNA or RNA
• C12N 15/81 - Vectors or expression systems specially adapted for eukaryotic hosts for fungi for yeasts
• C12Q 1/37 - Measuring or testing processes involving enzymes, nucleic acids or microorganismsCompositions thereforProcesses of preparing such compositions involving hydrolase involving peptidase or proteinase
• C40B 40/02 - Libraries contained in or displayed by microorganisms, e.g. bacteria or animal cellsLibraries contained in or displayed by vectors, e.g. plasmidsLibraries containing only microorganisms or vectors
• C40B 40/08 - Libraries containing RNA or DNA which encodes proteins, e.g. gene libraries

Abstract

Disclosed are mesenchymal stem cells genetically engineered to express pigment epithelium-derived factor (PEDF), or overexpress PEDF in comparison to parental cells. According to one embodiment, a pharmaceutical composition and a health functional food, which comprise same, can be effectively used in the prevention, alleviation or treatment of damage to epithelial cells or aging-associated diseases, retinal diseases, or liver diseases.

IPC Classes  ?

• C12N 5/0775 - Mesenchymal stem cellsAdipose-tissue derived stem cells
• A61P 1/16 - Drugs for disorders of the alimentary tract or the digestive system for liver or gallbladder disorders, e.g. hepatoprotective agents, cholagogues, litholytics
• A61P 27/02 - Ophthalmic agents
• A23L 33/10 - Modifying nutritive qualities of foodsDietetic productsPreparation or treatment thereof using additives

Abstract

The present invention relates to a skin-whitening and antioxidant cosmetic composition comprising silkworm hemolymph-derived low-molecular material, the material having a molecular weight of less than 10 kDa. The silkworm hemolymph-derived low-molecular material utilizes material which was conventionally discarded, and thus has excellent economic efficiency, and has excellent safeness for skin and excellent skin whitening and antioxidant effects, and the high-yield production thereof is possible, and thus the material may be usefully employed for a skin-whitening and antioxidant cosmetic composition.

IPC Classes  ?

• A61K 8/98 - Cosmetics or similar toiletry preparations characterised by the composition containing materials, or derivatives thereof, of undetermined constitution of animal origin
• A61Q 19/00 - Preparations for care of the skin
• A61Q 19/02 - Preparations for care of the skin for chemically bleaching or whitening the skin

Abstract

A composition according to the present invention is not only able to inhibit the growth of cancer cells, but also very effectively inhibit metastasis of cancer cells into other tissues, and thus can be used very effectively to prevent, ameliorate or treat cancer, as well as to inhibit metastasis of cancer.

IPC Classes  ?

• A61K 31/136 - Amines, e.g. amantadine having aromatic rings, e.g. methadone having the amino group directly attached to the aromatic ring, e.g. benzeneamine
• A61K 31/18 - Sulfonamides
• A61K 31/4453 - Non-condensed piperidines, e.g. piperocaine only substituted in position 1, e.g. propipocaine, diperodon
• A61K 31/495 - Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with two nitrogen atoms as the only ring hetero atoms, e.g. piperazine
• A61K 45/06 - Mixtures of active ingredients without chemical characterisation, e.g. antiphlogistics and cardiaca
• A61P 35/00 - Antineoplastic agents
• A23L 33/10 - Modifying nutritive qualities of foodsDietetic productsPreparation or treatment thereof using additives
• A61K 8/41 - Amines
• A61K 8/49 - Cosmetics or similar toiletry preparations characterised by the composition containing organic compounds containing heterocyclic compounds

Abstract

The present invention pertains to: a composition for culturing natural killer cells; a kit; and a method using same. According to a composition for culturing natural killer cells according to an aspect, and a method for culturing natural killer cells using same, when culturing natural killer cells from peripheral blood mononuclear cells, the natural killer cells can be proliferated in large quantities, and the activation or inhibition of the natural killer cells, as well as the expansion of the natural killer cells, can be promoted by culturing the natural killer cells in a medium containing a composition for culturing natural killer cells, the composition containing magnetic beads having an activating receptor ligand, an inhibitory receptor ligand, a costimulatory receptor ligand, a cytokine, a cytokine receptor, an immune checkpoint ligand, a blocking antibody, or a combination thereof attached to at least one side. Therefore, the natural killer cells thus cultured can be advantageously used as an immune cell therapeutic agent. Furthermore, the magnetic beads can be easily removed from the medium, thus providing convenience and cost-effectiveness, and the present invention uses safe magnetic beads, thus having excellent clinical safety.

IPC Classes  ?

• C12N 5/0783 - T cellsNK cellsProgenitors of T or NK cells

Abstract

The present invention relates to a pharmaceutical composition for preventing or treating metabolic diseases. A composition according to the present invention very effectively lowers blood glucose when administered to an individual afflicted with a metabolic disease, thereby being very suitably usable in the prevention, alleviation or treatment of metabolic diseases.

IPC Classes  ?

• A61K 31/136 - Amines, e.g. amantadine having aromatic rings, e.g. methadone having the amino group directly attached to the aromatic ring, e.g. benzeneamine
• A61K 31/145 - Amines, e.g. amantadine having sulfur atoms, e.g. thiurams (N—C(S)—S—C(S)—N or N—C(S)—S—S—C(S)—N)Sulfinylamines (—N=SO)Sulfonylamines (—N=SO2)
• A61K 31/18 - Sulfonamides
• A61K 31/495 - Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with two nitrogen atoms as the only ring hetero atoms, e.g. piperazine
• A61K 31/4453 - Non-condensed piperidines, e.g. piperocaine only substituted in position 1, e.g. propipocaine, diperodon
• A61P 3/00 - Drugs for disorders of the metabolism
• A23L 33/10 - Modifying nutritive qualities of foodsDietetic productsPreparation or treatment thereof using additives